| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (Tesaro) 4010-01-001 / GARNET | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors | Elit, Dr Laurie | Open to recruitment | NCT02715284 |
| (Ayala) AL-ACC-01 / ACCURACY | A Phase 2, Open-Label, Single-Arm, Multi-Center Study Of AL101 (BMS-906024) In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations | Hotte, Dr Sebastien | Open to recruitment | NCT03691207 |
| (Merck) MK-3475-587 / KEYNOTE 587 | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial | McWhirter, Dr Elaine | Recruitment on hold - COVID-19 | NCT03486873 |
| (UHN) OCTANE | Ontario-wide Cancer TArgeted Nucleic acid Evaluation (OCTANE) | Hotte, Dr Sebastien | Recruitment on hold - COVID-19 | NCT02906943 |
| (CCTG) IND.238 | A Phase II Study of Durvalumab Retreatment in Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity | Ellis, Dr Peter | Recruitment on hold - COVID-19 | NCT03847649 |
| (HHS) CRUSSH | Stereotactic body radiotherapy (SBRT) boost following urgent 3D conformal radiotherapy in the treatment of metastatic epidural spinal cord compression (SCC): A phase I feasibility trial | Schnarr, Dr Kara | Recruitment on hold - COVID-19 | NCT03529708 |
| (IMV) Immunovac / P1719-SUR-Z11 | A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced and Recurrent Solid Tumours | Hirte, Dr Hal | Recruitment on hold - COVID-19 | NCT03836352 |
| (Roche) BP29842 | AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION, PHASE IA/IB STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE CONSISTING OF INTERLEUKIN 2 VARIANT (IL-2v) TARGETING FIBROBLAST ACTIVATION PROTEIN- (FAP), AS A SINGLE AGENT (PART A) OR IN COMBINATION WITH TRASTUZUMAB OR CETUXIMAB (PART B OR C) | Hotte, Dr Sebastien | Recruitment on hold - COVID-19 | NCT02627274 |
Find a Trial
Contact Us